SLC5A5 and neoplasm: In line with this, clonal tracking (Figure 5C) showed an overlap between clones from t1 and t2 in the MV-NIS and MV-NIS plus anti-PD-1 combination treatment groups, which might represent virus-reactive or tumor-reactive T cells.